Blogs about Biotechnology, Pharmaceutical and Healthcare

21:25 EDT 27th July 2015 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 40,000+

Monday 27th July 2015

Headaches: Treatment depends on your diagnosis and symptoms

New Drug for Blood Cancers Now in Five Phase II Clinical Trials

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

Hear This: Dolby Family Puts More Cash Into Alzheimer Alternatives

After a battle with Alzheimer’s disease, audio engineering pioneer Ray Dolby died in 2013. Now his family is using the fortune he left behind to help find treatments that take a different tack than much of the work in the field to date. Through...

Healthtech Startup ConsortiEX Closes $1M Round Led By Open Prairie

ConsortiEX, a healthcare IT startup with roots in both Wisconsin and Massachusetts, has closed a $1 million funding round led by Open Prairie Ventures, the company announced today. ConsortiEX developed an ordering and tracking software system for the...

AstraZeneca Pays for Personal Health Coaches, Develops Other Health Apps

I need to confess that at the start that I am suspicious when a pharmaceutical company offers to pay for anything on behalf of patients. Such programs usually have a strong link to the company's bottom line. I cite as evidence my previous note about ...

UC San Diego Health and La Jolla Institute Announce New Affiliation

UC San Diego Health, with the University of California, San Diego School of Medicine, has entered into a multi-year affiliation agreement with La Jolla Institute for Allergy and Immunology (LJI) designed to deepen existing collaborative relationships, boost basic research of diseases of the immune system and more quickly introduce new clinical treatments and therapies.

Lombard's (EVAR) CEO Simon Hubbert on Q2 2015 Results - Earnings Call Transcript

Biotech Bubble Burst? Micro-Burst?

The biotech valuations are getting hit. This is no surprise. We have some mild surprise that this didn't happen earlier in the Summer. It's the traditional time for the doldrums on the street.Nevertheless, barring a national malaise, we expect to come out of it faster than the usual bubble bursting.A while back, we wrote our series on "The Biotech Bubble". For a number of reasons, we think it will...

Titan Pharma plans reverse split, NASDAQ listing

Titan Pharmaceuticals (OTCQB:TTNP) will ask shareholders at the annual meeting on Aug. 24 for approval of a reverse stock split within the range of 1-for-3 and 1-for-8 at any time prior to June 30, 2016. “We believe that enabling our board to set the ratio within the stated range will provide us with the flexibility […]

UCSD scientists praise La Jolla Institute alliance

La Jolla Institute's basic science in immunology complement UCSD's clinical prowess.

Wall Street Buying Shire’s Rationale For Sluggish Earnings

Shire remains on track for 2016 and 2020 sales targets, CEO says, as second quarter flatness was caused by foreign exchange impacts and generic competition to ADHD drug Intuniv.

Generic Drug Industry Scandal: Convicted FDA Reviewer Is Freed From Debarment

Twenty-five years after he pled guilty to taking payments from companies, former FDA review chemist David Brancato gets FDA to terminate his debarment; several industry execs won terminations years ago.

Schizophrenia's 'Rosetta Stone' gene identified

Scientists have identified a critical function of what they believe to be schizophrenia's "Rosetta Stone" gene that could hold the key to decoding the function of all genes involved in the disease. The breakthrough has revealed a vulnerable period in...

Court Rules UC San Diego is Rightful Owner of Alzheimer’s Disease Cooperative Study Data

On Friday, July 24, Superior Court Judge Judith F. Hayes found in favor of the University of California Regents’ request for a preliminary injunction to restore rightful custody and control of Alzheimer’s Disease Cooperative Study (ADCS) data to UC San Diego.

Fresenius: Great Growth But Needs To Improve Customer Service

French Drug Industry Group Kicked Off Key Gov't Committee

France will eliminate industry seat on the nation's HTA transparency panel, in apparent continuing Mediator fall-out.

Magellan Health's (MGLN) CEO Barry Smith on Q2 2015 Results - Earnings Call Transcript

What, exactly, does a “real doctor” look like?

A guest column by the American College of Physicians, exclusive to KevinMD.com. In the spring of 2009, I represented the American College of Physicians (ACP) at a meeting in Washington of health policy experts discussing payment reform. When I arrived at the cocktail reception the night before the meeting, a well-known medical leader not known to be […]

Is Gilead A Buy Pre Earnings?

Raleigh-Durham Roundup: Chimerix, vTv, Biotech Center, & More

Here are headlines from the past week in North Carolina biotech and cleantech news. —A Chimerix (NASDAQ: CMRX) antiviral being studied as a smallpox countermeasure showed positive results in a trial evaluating the drug in animals. The Durham co...

Beer Out as Struggling Aegerion Shuffles Leadership Ranks

It’s been a tumultuous few years for Aegerion Pharmaceuticals, marred by a stalled drug launch, the rise of new competitors, and a plummeting stock. And today its embattled CEO is leaving the company. Cambridge, MA-based Aegerion (NASDAQ: AEGR) sai...

Cellular Biomedicine (CBMG) Note 07-27-15

CBMG Receives CFDA OK for Non-Cryopreservation Cell & Tissue Kits CBMG Closes Acquisition of CD40LGVAX Lung Cancer Vaccine Combo Trial with Bristol-Myers Nivolumab PD-1 at Moffitt for U.S. Market Download Full 11-Page Note with Important Disclosures: Morning Note 07-27-15 CBMG The recent focus for CBMG has been on their immuno-oncology pipeline for CAR-T (CD19, CD20, CD30, EGFR/HER1) and the r...

Dollar Plagues Pharma Earnings, But Did The Street Get It Right?

Sale Of Allergan Generics To Teva Pharmaceuticals Adds Interesting Twist To Generic Drug Saga

Amarantus unit sets up strategic advisory committee

Amarantus Diagnostics, a unit of Amarantus BioScience Holdings (OTCQX:AMBS), has established a three-person strategic advisory committee (SAC) to focus on advancing and deriving the full value of the company’s diagnostics business. Amarantus Diagnostics is developing tests for multiple sclerosis and Alzheimer’s disease. The SAC includes Philippe Goix, Steven Guillen and Brian Ward. ...



Advertisement
 
Advertisement